Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAmati Aim Vct Regulatory News (AMAT)

  • There is currently no data for AMAT

Update on Offer for Subscription

15 Dec 2021 07:00

RNS Number : 6606V
Amati AIM VCT PLC
15 December 2021
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY JURISDICTION FOR WHICH THE SAME COULD BE UNLAWFUL. THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER OF SECURITIES FOR SALE IN ANY JURISDICTION, INCLUDING IN THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA.

 

Amati AIM VCT plc

15 December 2021

 

Amati AIM VCT plc (the "Company")

Legal Entity Identifier: 213800HAEDBBK9RWCD25

Update on offer for subscription

The Board of Amati AIM VCT plc (the "Company") announced on 28 July 2021 that the Company had published a prospectus (the "Prospectus") in connection with proposals to raise up to £40,000,000 (with an over-allotment facility to raise up to a further £25,000,000), by way of an offer for subscription of new ordinary shares (the "Offer"). Full details of the Offer are contained in the Prospectus.

The Company announced on 4 August 2021 that £40,000,000 had been raised under the Offer and that the Board had decided not to utilise the over-allotment facility at that time. However, the Company has continued to identify attractive investment opportunities and, having considered the current rate of investment activity, the Board is pleased to announce that it intends to utilise the over-allotment facility and to re-open the Offer in February 2022, subject to market conditions.

The Company will make a further announcement in relation to the re-opening of the Offer in due course.

The Prospectus is available at www.amatiglobal.com and https://data.fca.org.uk/#/nsm/nationalstoragemechanism. For further information, please contact the investor line at Amati Global Investors on 0131 503 9115 or by email at info@amatiglobal.com.

Notes

This Announcement is an advertisement for the purposes of the Prospectus Regulation Rules of the UK Financial Conduct Authority ("FCA") and is not a prospectus. This Announcement does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to subscribe for or to acquire, any ordinary shares in Amati AIM VCT plc (the "Company") in any jurisdiction, including in or into Australia, Canada, Japan, the Republic of South Africa, the United States or any member state of the EEA (other than any member state of the EEA where the Company's securities may be lawfully marketed). Investors should not subscribe for or purchase any ordinary shares referred to in this Announcement except on the basis of information in the prospectus (the "Prospectus") in its final form, published on 28 July 2021 by Amati AIM VCT plc in connection with the proposed admission of new ordinary shares to the premium segment of the Official List of the FCA and to trading on London Stock Exchange plc's main market for listed securities. A copy of the Prospectus is available for inspection, subject to certain access restrictions, from the Company's registered office, for viewing at the National Storage Mechanism at https://data.fca.org.uk/#/nsm/nationalstoragemechanism and on the Company's website (www.amatiglobal.com). Approval of the Prospectus by the FCA should not be understood as an endorsement of the securities that are the subject of the Prospectus. Potential investors are recommended to read the Prospectus before making an investment decision in order to fully understand the potential risks and rewards associated with a decision to invest in the Company's securities.

This Announcement does not constitute a recommendation concerning the Company or the Offer. The price and value of securities and any income from them can go down as well as up. Past performance is not a guide to future performance and prospective investors may not receive any return from the Company. Before purchasing any securities of the Company, persons viewing this Announcement should ensure that they fully understand and accept the risks set out in the Prospectus. Information in this Announcement or any of the documents relating to the Company or the Offer cannot be relied upon as a guide to future performance. Potential investors should consult a professional adviser as to the suitability of the Offer for them.

The information in this Announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this Announcement or its accuracy or completeness. This Announcement does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any securities of the Company or any other securities nor shall it (or any part of it) or the fact of its distribution, form the basis of, or be relied on in connection with, any contract therefor.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
OUPEANALFEAFFFA
Date   Source Headline
8th Oct 20213:49 pmRNSNet Asset Value(s)
6th Oct 20219:38 amRNSTransaction in Own Shares
4th Oct 20216:06 pmRNSHalf-year Report
1st Oct 20216:23 pmRNSNet Asset Value(s)
1st Oct 20218:34 amRNSTotal Voting Rights
27th Sep 20218:57 amRNSNet Asset Value(s)
20th Sep 20218:53 amRNSNet Asset Value(s)
15th Sep 20218:48 amRNSTransaction in Own Shares
13th Sep 20218:46 amRNSTransaction in Own Shares
10th Sep 20213:51 pmRNSNet Asset Value(s)
2nd Sep 20218:54 amRNSNet Asset Value(s)
2nd Sep 20218:27 amRNSTotal Voting Rights
31st Aug 202112:03 pmRNSNet Asset Value(s)
25th Aug 20219:53 amRNSIssue of Equity
23rd Aug 20218:46 amRNSNet Asset Value(s)
16th Aug 20218:44 amRNSNet Asset Value(s)
13th Aug 20211:13 pmRNSTransaction in Own Shares
13th Aug 20219:01 amRNSDirector/PDMR Shareholding
11th Aug 20216:24 pmRNSDirector/PDMR Shareholding
10th Aug 202112:14 pmRNSIssue of Equity
9th Aug 20218:36 amRNSNet Asset Value(s)
4th Aug 20213:30 pmRNSOffer for Subscription - Update
3rd Aug 202112:03 pmRNSNet Asset Value(s)
2nd Aug 20218:56 amRNSTotal Voting Rights
28th Jul 20215:14 pmRNSOffer for subscription and Issue of Prospectus
26th Jul 202110:21 amRNSDirector/PDMR Shareholding
26th Jul 202110:17 amRNSIssue of Equity - DRIS
26th Jul 20218:23 amRNSNet Asset Value(s)
19th Jul 20211:48 pmRNSTransaction in Own Shares
19th Jul 202111:42 amRNSNet Asset Value(s)
16th Jul 202112:25 pmRNSTransaction in Own Shares
12th Jul 20218:38 amRNSNet Asset Value(s)
2nd Jul 202110:35 amRNSNet Asset Value(s)
1st Jul 20218:56 amRNSTotal Voting Rights
25th Jun 20215:37 pmRNSNet Asset Value(s)
22nd Jun 20215:22 pmRNSUpdate on Offer for Subscription
22nd Jun 20219:10 amRNSTransaction in Own Shares
21st Jun 202111:54 amRNSTransaction in Own Shares
18th Jun 20215:27 pmRNSNet Asset Value(s)
14th Jun 202110:02 amRNSNet Asset Value(s)
14th Jun 20219:43 amRNSTransaction in Own Shares
10th Jun 20217:00 amRNSDirectorate Change
10th Jun 20217:00 amRNSResult of AGM
7th Jun 20218:42 amRNSNet Asset Value(s)
2nd Jun 20219:09 amRNSNet Asset Value(s)
1st Jun 20211:11 pmRNSTotal Voting Rights
27th May 20211:15 pmRNSDirectorate Change
21st May 20215:35 pmRNSNet Asset Value(s)
17th May 20219:03 amRNSNet Asset Value(s)
12th May 202111:56 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.